Cobolimab

Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC) [1][2][3].

Product Specifications

CAS Number

[2022215-65-0]

Product Name Alternative

TSR-022; GSK4069889

UNSPSC

12352203

Target

Tim3

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cobolimab.html

Purity

98.00

Solubility

10 mM in DMSO

Smiles

[Cobolimab]

Molecular Weight

(142.84 kDa)

References & Citations

[1]Falchook G S, et al. Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER) [J]. 2022.|[2]Markham A. Dostarlimab: First Approval. Drugs. 2021 Jul;81 (10) :1213-1219.|[3]Kuang Z, et al. A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy. Antib Ther. 2020 Nov 9;3 (4) :227-236. |[4]Sun CY, et al. T cell exhaustion drives osteosarcoma pathogenesis. Ann Transl Med. 2021 Sep;9 (18) :1447.